Glennie MJ[au] - Search Results

Year	Number of Results
1982	1
1984	1
1985	3
1986	2
1987	7
1988	3
1989	1
1990	3
1991	9
1992	2
1993	2
1994	1
1995	6
1996	3
1997	5
1998	3
1999	4
2000	6
2001	5
2002	6
2003	7
2004	6
2005	2
2006	2
2007	4
2008	7
2009	6
2010	7
2011	5
2012	5
2013	9
2014	7
2015	10
2016	5
2017	4
2018	4
2019	3
2020	4
2021	1
2022	2

1

Influence of immunoglobulin isotype on therapeutic antibody function.

Beers SA, Glennie MJ, White AL. Beers SA, et al. Among authors: glennie mj. Blood. 2016 Mar 3;127(9):1097-101. doi: 10.1182/blood-2015-09-625343. Epub 2016 Jan 13. Blood. 2016. PMID: 26764357 Free PMC article. Review.

2

Rituximab: mechanisms and applications.

Johnson PW, Glennie MJ. Johnson PW, et al. Among authors: glennie mj. Br J Cancer. 2001 Nov 30;85(11):1619-23. doi: 10.1054/bjoc.2001.2127. Br J Cancer. 2001. PMID: 11742477 Free PMC article. Review. No abstract available.

3

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ. White AL, et al. Among authors: glennie mj. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Cancer Immunol Immunother. 2013. PMID: 23543215 Review.

4

Anti-CD20 monoclonal antibodies: historical and future perspectives.

Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Lim SH, et al. Among authors: glennie mj. Haematologica. 2010 Jan;95(1):135-43. doi: 10.3324/haematol.2008.001628. Epub 2009 Sep 22. Haematologica. 2010. PMID: 19773256 Free PMC article. Review.

5

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.

Yu X, James S, Felce JH, Kellermayer B, Johnston DA, Chan HTC, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Watanabe Y, Crispin M, French RR, Duriez PJ, Douglas LR, Glennie MJ, Cragg MS. Yu X, et al. Among authors: glennie mj. Commun Biol. 2021 Jun 23;4(1):772. doi: 10.1038/s42003-021-02309-5. Commun Biol. 2021. PMID: 34162985 Free PMC article.

6

Therapeutic potential of immunostimulatory monoclonal antibodies.

Gray JC, Johnson PW, Glennie MJ. Gray JC, et al. Among authors: glennie mj. Clin Sci (Lond). 2006 Aug;111(2):93-106. doi: 10.1042/CS20060024. Clin Sci (Lond). 2006. PMID: 16831129 Review.

7

Clinical trials of antibody therapy.

Glennie MJ, Johnson PW. Glennie MJ, et al. Immunol Today. 2000 Aug;21(8):403-10. doi: 10.1016/s0167-5699(00)01669-8. Immunol Today. 2000. PMID: 10916144 Review.

8

Signaling antibodies in cancer therapy.

Cragg MS, French RR, Glennie MJ. Cragg MS, et al. Among authors: glennie mj. Curr Opin Immunol. 1999 Oct;11(5):541-7. doi: 10.1016/s0952-7915(99)00010-2. Curr Opin Immunol. 1999. PMID: 10508709 Review.

9

Mechanisms of killing by anti-CD20 monoclonal antibodies.

Glennie MJ, French RR, Cragg MS, Taylor RP. Glennie MJ, et al. Mol Immunol. 2007 Sep;44(16):3823-37. doi: 10.1016/j.molimm.2007.06.151. Mol Immunol. 2007. PMID: 17768100 Review.

10

CD20 as a target for therapeutic type I and II monoclonal antibodies.

Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. Beers SA, et al. Among authors: glennie mj. Semin Hematol. 2010 Apr;47(2):107-14. doi: 10.1053/j.seminhematol.2010.01.001. Semin Hematol. 2010. PMID: 20350657 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results